Market closedNon-fractional
Eyenovia/EYEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Eyenovia
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
Ticker
EYEN
Sector
Healthcare
Trading on
NASDAQ
Industry
Pharmaceuticals
Headquarters
New York, United States
Employees
57
Website
www.eyenovia.com
Eyenovia Metrics
BasicAdvanced
$54M
Market cap
-
P/E ratio
-$0.75
EPS
1.71
Beta
-
Dividend rate
Price and volume
Market cap
$54M
Beta
1.71
Financial strength
Current ratio
0.878
Quick ratio
0.52
Long term debt to equity
434.569
Total debt to equity
915.081
Interest coverage (TTM)
-11.64%
Management effectiveness
Return on assets (TTM)
-68.07%
Return on equity (TTM)
-368.02%
Valuation
Price to revenue (TTM)
4,316.832
Price to book
22.9
Price to tangible book (TTM)
-9.67
Price to free cash flow (TTM)
-1.262
Growth
Earnings per share change (TTM)
0.64%
3-year revenue growth
-87.00%
3-year earnings per share growth
-4.25%
What the Analysts think about Eyenovia
Analyst Ratings
Majority rating from 4 analysts.
Eyenovia Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$11M
37.97%
Profit margin
0.00%
NaN%
Eyenovia Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.16
-$0.18
-$0.18
-$0.23
-
Expected
-$0.18
-$0.18
-$0.18
-$0.17
-$0.15
Surprise
-8.57%
0.00%
2.86%
31.93%
-
Eyenovia News
AllArticlesVideos
Eyenovia Announces Pricing of $5M Registered Direct Offering
GlobeNewsWire·1 week ago
Eyenovia, Inc. (EYEN) Q1 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Eyenovia stock?
Eyenovia (EYEN) has a market cap of $54M as of July 06, 2024.
What is the P/E ratio for Eyenovia stock?
The price to earnings (P/E) ratio for Eyenovia (EYEN) stock is 0 as of July 06, 2024.
Does Eyenovia stock pay dividends?
No, Eyenovia (EYEN) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next Eyenovia dividend payment date?
Eyenovia (EYEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Eyenovia?
Eyenovia (EYEN) has a beta rating of 1.71. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Eyenovia stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.